Latest News

Earlier menopause, APOE ε4, and age-related inflammation combine to accelerate memory decline, revealing key factors in women’s Alzheimer disease risk.

TMS: Menopause care isn’t one-size-fits-all—and that’s the problem. Wake Forest data reveal deep disparities in who gets treated and how.

In a subanalysis of the SELECT trial, semaglutide was associated with reduction in MACE across weight and waist circumference categories, independent of body fat.

TMS: New preliminary data show reduction in bothersome VMS as early as week 4, an effect that led to statistically significant improvements across other life domains.

TMS: New data pooled across clinical trials confirm elinzanetant’s consistent efficacy, safety, and sleep benefits across diverse populations of menopausal women.

TMS: Mediation analysis found that more than half of elinzanetant's sleep benefit occurs independently of nighttime hot flash reduction, challenging VMS-centric models.

TMS: Black women are up to 36% less likely to receive a prescription for systemic estrogen than White women, despite more acute and persistent VMS, authors said.

TMS: Findings from a large study presented at TMS 2025 counter previous reports suggesting menopause-specific effects on brain structure at midlife.